Welcome to our dedicated page for Yarrow Bioscience SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Yarrow Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Yarrow Bioscience's regulatory disclosures and financial reporting.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report passive beneficial ownership of Yarrow Bioscience, Inc. common stock. They collectively report beneficial ownership of 266,756 shares of common stock, representing 9.99% of the outstanding class based on 2,669,788 shares outstanding.
The Master Fund directly holds 266,309 shares of common stock and 967,360 pre-funded warrants with an exercise price of $0.0001 per share, subject to a 9.99% Beneficial Ownership Limitation. As of this filing, that limitation permits exercise of pre-funded warrants for only 447 additional shares. Voting and dispositive power over 266,756 shares is reported as shared among the three reporting persons.
Yarrow Bioscience, Inc. has a significant shareholder group led by RTW Fund Group GP, LLC and its managing member, Roderick Wong, M.D. They report beneficial ownership of 266,307 shares of common stock, representing 9.99% of the class, based on 2,669,788 shares outstanding as of July 29, 2026.
The RTW-related entity holds all of these shares, with RTW Fund Group and Dr. Wong having shared voting and shared dispositive power over 266,307 shares and no sole voting or dispositive power. Their ownership is structured to stay at or below a 9.99% beneficial ownership limitation, because additional shares are issuable upon exercise of pre-funded warrants but are expressly excluded from the reported position to comply with that cap. Dividends or sale proceeds on the reported shares are directed to the RTW entity that directly holds the stock.
Yarrow Bioscience, Inc. reports that an affiliated RTW Entity managed by RTW Fund Group GP, LLC exchanged 133,290 shares of common stock for pre-funded warrants to purchase the same number of shares on July 29, 2026. Following this restructuring, the RTW Entity holds 8,949,719 pre-funded warrants and 266,307 common shares, all indirectly, with beneficial ownership disclaimed except to the extent of pecuniary interest. The pre-funded warrants have a $0.0001 exercise price, no expiration, and a 9.99% beneficial ownership cap.
Yarrow Bioscience, Inc. entered into an exchange agreement with an existing stockholder on July 29, 2026. The stockholder exchanged 133,290 shares of common stock for pre-funded warrants to purchase the same number of shares at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and remain outstanding until fully exercised.
A Beneficial Ownership Limitation restricts exercises that would push the holder above 9.99% of outstanding common stock, adjustable up to 19.99% with 61 days’ notice. After the exchange, Yarrow Bioscience has 2,669,788 shares of common stock outstanding and pre-funded warrants to purchase 25,914,530 shares outstanding.
RTW Fund Group GP, LLC and Roderick Wong, M.D., reported as ten percent owners of Yarrow Bioscience, Inc., disclose indirect holdings received in a July 27, 2026 merger: 399,597 shares of common stock and pre-funded warrants exercisable at $0.0001 for 8,816,429 shares, subject to a 9.99% beneficial ownership cap. The securities are held by an affiliated entity managed by RTW Fund Group, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
Yarrow Bioscience, Inc. director Ashiya Mona reported a grant of stock options covering 15,435 shares of common stock on July 27, 2026. The options have a $28.5600 exercise price, expire on July 27, 2036, and vest in full on the earlier of July 27, 2027 or the next annual meeting of stockholders, subject to continued service. Under an agreement, Mona must transfer any securities issued, or their economic benefit, to OrbiMed Advisors LLC, which will provide them to OrbiMed Private Investments X, LP.
Zeronda Tyler, a director of Yarrow Bioscience, Inc., received a grant of stock options covering 185,798 shares of common stock on July 27, 2026. The options have an exercise price of $28.56 per share, expire on July 27, 2036, and vest one quarter on July 27, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service.
Yarrow Bioscience, Inc. describes the initial indirect holdings of OrbiMed-related reporting persons following the July 27, 2026 merger in which a wholly owned subsidiary of VYNE Therapeutics Inc. merged into Yarrow and VYNE adopted the Yarrow name. The OrbiMed funds hold common stock and Pre-Funded Warrants for issuer common stock at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership blocker. Each share of former Yarrow common stock converted into 0.7171 shares of issuer common stock, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Yarrow Bioscience, Inc. director Ashiya Mona reports her indirect interest in securities held by OrbiMed-managed investment funds. These include pre-funded warrants to acquire 4,084,827 and 583,545 shares of common stock at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership blocker. The disclosure also describes a merger in which a VYNE Therapeutics Inc. subsidiary combined with Yarrow, after which VYNE was renamed “Yarrow Bioscience, Inc.” and each Yarrow share was exchanged for 0.7171 share of the renamed company’s common stock. The reporting person and related OrbiMed entities disclaim beneficial ownership beyond any pecuniary interest.
Yarrow Bioscience, Inc. reports initial insider holdings for director William Richard White. Following a merger effective July 27, 2026, a wholly owned subsidiary of VYNE Therapeutics Inc. merged into the prior Yarrow entity, and VYNE changed its name to Yarrow Bioscience, Inc. White holds a stock option directly to purchase 87,820 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on April 17, 2036. One quarter of this option will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to his continued service.